Author

Julie J.G. Kephart

Observed names: Julie Grondin Kephart, Julie Kephart

Institutions: Duke University, Duke Cancer Institute

Observed institutions: Duke University, Duke Medical Center, Duke Cancer Institute

OpenAlex ID: A5045891896

Alveolar rhabdomyosarcoma–associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression

2013 · Lisa E.S. Crose, Kathleen A. Galindo, et al. · Journal of Clinical Investigation · 124

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

2017 · Andrew J. Armstrong, Susan Halabi, et al. · European Journal of Cancer · 95

Embryonic Signaling Pathways and Rhabdomyosarcoma: Contributions to Cancer Development and Opportunities for Therapeutic Targeting

2012 · Brian Belyea, Julie Grondin Kephart, et al. · Sarcoma · 52

PDF

A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate‐resistant prostate cancer

2021 · Daniel J. George, Susan Halabi, et al. · Cancer · 43

Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).

2018 · Daniel J. George, Elisabeth I. Heath, et al. · Journal of Clinical Oncology · 37

Prospective clinical trial of disulfiram plus copper in men with metastatic castration‐resistant prostate cancer

2022 · Tian Zhang, Julie Kephart, et al. · The Prostate · 30

Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma

2015 · Julie J.G. Kephart, Rosanne G.J. Tiller, et al. · Clinical Cancer Research · 22

Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial

2016 · Andrew J. Armstrong, Michael S. Humeniuk, et al. · The Prostate · 10

Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).

2020 · Tian Zhang, Julie Kephart, et al. · Journal of Clinical Oncology · 8

A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab.

2020 · Landon Carter Brown, Kunal Desai, et al. · Journal of Clinical Oncology · 5

Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).

2024 · Daniel J. George, Susan Halabi, et al. · Journal of Clinical Oncology · 4

PDF

Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP).

2026 · Andrew J. Armstrong, Lauren Howard, et al. · Journal of Clinical Oncology · 3

Genetic ancestry concordant RNA splicing in prostate cancer involves oncogenic genes and associates with recurrence

2025 · Muthana Al Abo, Wen-Chi Foo, et al. · npj Precision Oncology · 2

PDF

Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab.

2020 · Kunal Desai, Landon Carter Brown, et al. · Journal of Clinical Oncology · 1

Genetic ancestry–concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration‐resistant prostate cancer

2026 · Sean A. Piwarski, Lauren E. Howard, et al. · Cancer

Predictive associations between serum oxo-androgens, race, and radiographic progression-free survival (rPFS) among patients treated with apalutamide (Apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study.

2026 · Robert Bruce Montgomery, Lauren Howard, et al. · Journal of Clinical Oncology

PDF

Abstract C117: Serum dehydroepiandrosterone sulfate (DHEAS) and race associated with longer survival in patients (pts) treated with apalutamide (Apa) and abiraterone acetate (AA) plus prednisone (P) in the PANTHER study

2025 · Daniel J. George, Lauren E. Howard, et al. · Cancer Epidemiology Biomarkers & Prevention

Abstract C116: Genetic ancestry concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer

2025 · Sean A. Piwarski, Lauren E. Howard, et al. · Cancer Epidemiology Biomarkers & Prevention

Overall survival outcomes with sipuleucel-T (Sip-T) among Black men with metastatic castrate-resistant prostate cancer (mCRPC) also treated with androgen receptor pathway inhibitors (ARPI).

2025 · Patrick O'Shea, Matthew Labriola, et al. · Journal of Clinical Oncology

PDF

Predictive associations between serum dehydroepiandrosterone sulfate (DHEAS) and race among patients (pts) treated with apalutamide (apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study.

2025 · Daniel J. George, Lauren Howard, et al. · Journal of Clinical Oncology

Ceramides and response to dual secondary hormonal therapy in metastatic castration-resistant prostate cancer (mCRPC) among Black men.

2025 · Jennifer A. Freedman, Sean Piwarski, et al. · Journal of Clinical Oncology

PDF

Suboptimal suppression of serum androgen levels among men treated with apalutamide and abiraterone acetate plus prednisone compared with abiraterone acetate plus prednisone alone.

2025 · Elahe A. Mostaghel, Jennifer A. Freedman, et al. · Journal of Clinical Oncology

PDF

Supplementary Table 1 from Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma

2023 · Julie J.G. Kephart, Rosanne G.J. Tiller, et al.

Supplementary Figure 4 from Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma

2023 · Julie J.G. Kephart, Rosanne G.J. Tiller, et al.

Supplementary Figure 3 from Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma

2023 · Julie J.G. Kephart, Rosanne G.J. Tiller, et al.

Works count: 44

Citation count: 436

H-index: 8

I10-index: 8